Aerodynamic Particle Size Distribution (APSD) Testing System for Nebulized Liquid Formulations – HRH-JC Series

Overview

The HRH-JC Series Aerodynamic Particle Size Distribution (APSD) Testing System is a purpose-built, regulatory-compliant apparatus engineered to characterize the aerodynamic behavior of liquid formulations intended for nebulization in respiratory drug delivery. Designed in strict alignment with pharmacopoeial standards—including USP <601> Aerosols, Nasal Sprays, and Metered Dose Inhalers; Ph. Eur. 2.9.18 Aerodynamic Assessment of Inhaled Products; and ChP (2020 Edition) General Chapter 0951 “Determination of Fine Particle Fraction for Inhalation Preparations”—this system enables quantitative measurement of mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and fine particle fraction (FPF) under controlled flow conditions. The system operates on the principle of inertial impaction: aerosolized droplets generated by a calibrated medical-grade nebulizer are drawn through a multi-stage cascade impactor (the next-generation pharmaceutical rotating disk impactor), where particles separate by aerodynamic size due to differential inertia at defined flow rates (typically 60–100 L/min, per ICH Q5A and ISO 27427 guidance). This physical separation allows gravimetric or assay-based quantification of deposited mass across aerodynamically defined cut-points—critical for establishing in vitro equivalence (IVIVC) and supporting regulatory submissions to FDA, EMA, and NMPA.

Key Features

• Integrated intelligent vacuum pump with closed-loop digital flow control, maintaining ±2% accuracy across the 30–120 L/min operational range;
• High-precision thermal mass flow meter (NIST-traceable calibration, ±1.0% reading accuracy) for real-time volumetric flow monitoring and logging;
• Next-generation pharmaceutical rotating disk impactor (RDI) with six-stage collection geometry, compliant with USP <601>, Ph. Eur. 2.9.18, and ChP 0951 requirements for nebulized liquids;
• Dedicated liquid formulation nebulizer interface with standardized mounting, pressure regulation, and temperature-stabilized reservoir holder (20–25°C ambient operation);
• Modular stainless-steel and anodized aluminum construction ensuring corrosion resistance, cleanability, and long-term dimensional stability;
• Pre-aligned impactor stages with certified nozzle diameters and inter-stage spacing per pharmacopoeial tolerances (±0.02 mm);
• Optional integrated environmental sensor module (temperature, relative humidity, barometric pressure) for ISO 17025-compliant uncertainty budgeting.

Sample Compatibility & Compliance

The HRH-JC Series supports a broad range of aqueous and non-aqueous liquid formulations used in jet and ultrasonic nebulizers—including saline solutions, bronchodilator suspensions (e.g., albuterol sulfate), corticosteroid solutions (e.g., budesonide), and novel biopolymer-based delivery systems. All components meet ISO 13485:2016 design control requirements for medical device-associated testing equipment. The rotating disk impactor is validated per ASTM E2893–22 (“Standard Practice for Performance Verification of Cascade Impactors”) and includes full traceable documentation for installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ). Data integrity complies with FDA 21 CFR Part 11 requirements when paired with validated third-party data acquisition software.

Software & Data Management

While the base HRH-JC hardware operates as a stand-alone analog-digital hybrid platform, it is fully compatible with industry-standard GxP-compliant software suites (e.g., WinCAPA v6.2+, Copley Inhaler Testing Software v5.4+). Raw flow and timing data are exported via RS-485 or USB-C to external PCs for post-processing. Calibration certificates, impactor stage weights, and environmental logs are structured in CSV/Excel formats adhering to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available). Audit trails support GLP/GMP audit readiness, including user access logs, method version control, and electronic signature workflows.

Applications

• In vitro characterization of generic and innovator nebulized products for ANDA and MAA submissions;
• Formulation development screening: excipient effects on droplet breakup, evaporation kinetics, and MMAD shift;
• Stability assessment of liquid inhalers across accelerated and long-term storage conditions;
• Comparative testing against reference listed drugs (RLDs) per FDA Draft Guidance on Nebulized Drug Products (2022);
• Supporting quality-by-design (QbD) initiatives through design space mapping of nebulizer operating parameters (e.g., gas flow rate, solution viscosity, surfactant concentration);
• Method transfer between laboratories under ICH Q5B and WHO TRS 1010 Annex 9 frameworks.

FAQ

Does the HRH-JC Series meet FDA requirements for ANDA submissions?

Yes—the rotating disk impactor and overall system architecture conform to USP <601> and FDA’s 2022 Draft Guidance on Nebulized Drug Products, including specifications for flow control accuracy, impactor geometry, and environmental monitoring.
Can the system be qualified for GMP manufacturing environments?

Yes—full IQ/OQ/PQ protocols are available, and the system supports 21 CFR Part 11 compliance when integrated with validated software and procedural controls.
Is the impactor calibrated and certified prior to shipment?

Each HRH-JC impactor undergoes factory calibration using polystyrene latex (PSL) microspheres and receives a NIST-traceable certificate of conformance to Ph. Eur. 2.9.18 dimensional tolerances.
What nebulizer types are supported out-of-the-box?

The system interfaces with standard jet (e.g., Pari LC Sprint, Omron NE-U22) and ultrasonic (e.g., DeVilbiss Ultra-Neb 99) nebulizers via configurable mounting adapters and pressure regulators.
Is training and technical support provided internationally?

Huironghe offers remote and on-site operator training, SOP development assistance, and annual preventive maintenance packages with global service partners in EU, APAC, and LATAM regions.